GIF, which alternately shows physicians and the endoprostheses referred to on this website

Devices

Join the next generation of care in the treatment of aortoiliac occlusive disease

The latest generation of covered stent grafts

GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft)
GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface* (GORE® VIABAHN® Device)

 

VBX Stent Graft

Decide with data

5-year follow-up shows the VBX Stent Graft continues to be a long-term durable treatment option for complex aortoiliac occlusive disease (AIOD).1

The Gore VBX FLEX Clinical Study 3-year follow-up found the VBX Stent Graft to be a robust and durable treatment option for AIOD.2  Now, sustained patient benefit and durability are demonstrated through 5 years.

Physician-initiated 5-year VBX Stent Graft follow-up
 

Objective and methodology1
 

  • This physician-initiated study enrolled 59 of the initial 134 patients from 3 participating centers that were representative of the VBX FLEX Study 3-year follow-up cohort. 28 patients completed the 5-year follow-up.
  • The primary durability endpoint was long-term primary patency.

 

DURABLE CLINICAL OUTCOMES THROUGH 5 YEARS1:

89.5%

primary patency per lesion

96.1%

primary assisted patency per lesion

89.1%

freedom from target lesion revascularization per subject

SUSTAINED PATIENT BENEFIT THROUGH 5 YEARS1:

100%

of evaluated (n=28) patients improved ≥ 1 Rutherford category from baseline†,1

.15

improvement in mean resting ankle-brachial index (ABI)
(P < .001, .95 mean ABI) ‡

3x

improvement in median WIQ measures

The case for long-term durable clinical outcomes:

Case study 1: Restoring flow to a patient with stenosis at the aortoiliac bifurcation
Case study 2: Restoring flow in a patient with severe claudication and focal iliac calcification

GORE® VIABAHN® Device

Durable clinical outcomes and proven patency even in complex cases.§

VIABAHN® Device

GORE® VIABAHN® Device outcomes in iliac occlusive disease

Retrospective multicenter study, evaluating the performance of the GORE® VIABAHN® Device (n = 93) for the treatment of external iliac artery obstructive disease.

89.8%

Primary patency at 42 months3

91%

Secondary patency at 42 months3

94.6%

Limb salvage rate at 42 months3

* As used by Gore, PROPATEN Bioactive Surface refers to Gore’s proprietary CBAS® Heparin Surface.

† 59 subjects participated and 28 were available through the end of the study at 5-year follow-up. 

‡ (P < .001) Statistically significant change from pre-procedure.

§ Complex defined as TASC II classification C & D lesions.

  1. Holden A, Takele E, Hill A, et al. Long-Term Follow-up of Subjects With Iliac Occlusive Disease Treated With the Viabahn VBX Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy. 2023;0(0). doi:10.1177/15266028231165723.
  2. Panneton JM, Bismuth J, Gray BH, Holden A. Three-year follow-up of patients with iliac occlusive disease treated with the Viabahn Balloon-Expandable Endoprosthesis. Journal of Endovascular Therapy 2020;27(5):728-736.
  3. Squizzato, F., Mosquera-Rey, V., Zanabili Al-Sibbai, A. et al. Outcomes of Self-Expanding Covered Stents for the Treatment of External ILIAC Artery Obstructive Disease. Cardiovasc Intervent Radiol 46, 579–587 (2023). https://doi.org/10.1007/s00270-023-03370-9

eIFU Symbol

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

CBAS is a trademark of Carmeda AB, a wholly owned subsidiary of W. L. Gore & Associates, Inc

24PL2118-EN01

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.